focus -WSS

focus

author：explore 2025-10-01 21:47:53 - browse：615

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Doctor of U.S. President Joe Biden says he is fit for duty

focus

WSS

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Woman returns to dialysis after doctors remove transplanted pig kidney

Readout Newsletter: Beam, Prozac, "TechBio" and more

CDC advisory group OKs chikungunya vaccine

NEJM study measures Covid brain fog, impact on IQ

Color Health wants to make cancer screenings convenient

leisure time

focus

focus

Medicare details structure of new drug price negotiation program

Medicare Advantage isn’t working — for anyone

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

As demand for Covid shots wanes, Moderna seeks its next success

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Medicare proposal to cover medical devices draws a mixed reaction

FDA's Pazdur wants cancer trials to range beyond China alone

23andMe had bad news about my health. I wish a person had delivered it

Medicare Advantage isn’t working — for anyone

focus

Medicare Advantage isn’t working — for anyone

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Ionis drug prevents swelling attacks due to hereditary angioedema

See how much Covid

Doctor of U.S. President Joe Biden says he is fit for duty

NIH documents show early flaws of $1.6 billion long Covid program

focus

knowledge

hotspot

hotspot